Spirea

Spirea, a spin-out from the University of Cambridge, is developing the next generation of antibody drug conjugate cancer therapeutics which carry more drug payload to tumour cells resulting in greater efficacy and tolerability and the ability to treat more cancer patients. Visit the Spirea website:

https://www.spirea.co.uk/